Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Lancet
; 391(10117): 205-218, 2018.
Article
in English
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1064603
Responsible library:
BR79.1
Localization: BR79.1
ABSTRACT
BACKGROUND:
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease.METHODS:
In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospitals, clinics, or community centres in 33 countries. This paper reports on patients with coronary artery disease. Eligible patients with coronary artery disease had to have had a myocardial infarction in the past 20 years, multi-vessel coronary artery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-vessel coronary artery bypass graft surgery. After a 30-day run in period, patients were randomly assigned (111) to receive rivaroxaban (2·5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day). Randomisation was computer generated. Each treatment group was double dummy, and the patients, investigators, and central study staff were masked to treatment allocation. The primary outcome of the COMPASS trial was the occurrence of myocardial infarction, stroke, or cardiovascular death. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants...
Search on Google
Collection:
National databases
/
Brazil
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Cardiovascular Disease
/
Ischemic Heart Disease
/
Sense Organ Diseases
Database:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Main subject:
Coronary Artery Disease
/
Case-Control Studies
/
Aspirin
/
Rivaroxaban
Type of study:
Controlled clinical trial
/
Observational study
Language:
English
Journal:
Lancet
Year:
2018
Document type:
Article
Institution/Affiliation country:
ANMCO Research Center/IT
/
Bayer AG/DE
/
Bayer AG/US
/
Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School/US
/
Charles University/CZ
/
Collegium Medicum Jagiellonian University/PL
/
Department of Medicine, National University of Ireland/IE
/
Department of Medicine, Semmelweis University/HU
/
Department of Medicine, Turku University Central Hospital and Turku University/FI
/
Department of Medicine, University of Edinburgh/GB